

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (Original) A skin-care composition containing 20-O- $\beta$ -D-glucopyranosyl-20(S)-protopanaxatriol (ginsenoside F1) and (-)epigallocatechin-3-gallate (EGCG) as active ingredients.
2. (Original) The composition according to Claim 1, wherein said skin-care is obtained by the apoptosis-inhibitory effect of said active ingredients.
3. (Original) The composition according to Claim 2, wherein said apoptosis is apoptotic cell death induced by low dose of UV irradiation.
4. (Original) The composition according to Claims 2 or 3 , wherein said apoptosis-inhibitory effect is obtained by regulating the expression of Bcl-2.
5. (Original) The composition according to Claim 4, wherein said regulation of Bcl-2 expression is obtained by regulating the expression of Brn-3a.

6. (Currently amended) The composition according to ~~any one of Claims 1 to 5~~  
claim 1, wherein said ginsenoside F1 and EGCG are incorporated in a combined amount of  
0.0001% to 10% by weight based on the total weight of the composition.

7. (Currently amended) The composition according to ~~any one of Claims 1 to 5~~  
claim 1, wherein said ginsenoside F1 and EGCG are incorporated in a weight ratio of ~~1:0.1-10~~  
1 : 0.1 - 10.

8. (Original) An inhibitor of Rb protein dephosphorylation containing ginsenoside  
F1 and EGCG as active ingredients.

9. (Original) An inhibitor of skin damage for preventing cellular damage caused by  
exposure to ultraviolet rays, containing a combination of low concentrations of ginsenoside F1  
and EGCG as an active ingredient.

10. (Original) An external composition for skin care containing a combination of  
ginsenoside F1 and EGCG as an active ingredient.